Literature DB >> 3129955

Total intravenous anaesthesia with propofol and alfentanil by computer-assisted infusion.

J Schüttler1, S Kloos, H Schwilden, H Stoeckel.   

Abstract

The combination of propofol and alfentanil was administered to 20 patients for total intravenous anaesthesia during general surgery. The infusion rates for both drugs were controlled by microprocessors in order to institute constant blood levels adapted to the patients' varying needs. The mean blood level of propofol required for adequate hypnosis during anaesthesia was 2.42 micrograms/ml (SD 0.43). Awakening occurred 7.9 minutes (SD 3.4) after the end of the infusion, at a propofol blood level of 1.59 micrograms/ml (SD 0.34). The plasma level of alfentanil was 285 ng/ml (SD 72) during major noxious stimulation and 148 ng/ml (SD 56) during minor stimulation. The computer-assisted infusions showed a measured/predicted ratio of 1.01 (SD 0.28) for alfentanil and 0.88 (SD 0.22) for propofol. This indicates that the administration device used in this study is reasonably reliable. The technique of total intravenous anaesthesia was characterised by a smooth induction without significant haemodynamic alterations, by good control during anaesthesia and by a very fast recovery without major side effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129955     DOI: 10.1111/j.1365-2044.1988.tb09059.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  19 in total

1.  Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass.

Authors:  Luca La Colla; Andrea Albertin; Giorgio La Colla; Andrea Porta; Giorgio Aldegheri; Domenico Di Candia; Fausto Gigli
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

2.  Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogs.

Authors:  S-H Lee; J-L Ghim; M-H Song; H-G Choi; B-M Choi; H-M Lee; E-K Lee; Y-J Roh; G-J Noh
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

3.  Pharmacokinetic-based minibolus delivery as an alternative to continuous infusion for drugs that exhibit a biophase lag.

Authors:  S E Kern; D R Westenskow
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

4.  Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children.

Authors:  Byung-Moon Choi; Hyun-Gu Lee; Hyo-Jin Byon; Soo-Han Lee; Eun-Kyung Lee; Hee-Soo Kim; Gyu-Jeong Noh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-28       Impact factor: 2.745

5.  Total intravenous anaesthesia.

Authors:  J S Mallon; G Edelist
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

6.  Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation.

Authors:  Bo Rim Kim; Jaeseong Oh; Kyung-Sang Yu; Ho Geol Ryu
Journal:  Br J Clin Pharmacol       Date:  2020-02-18       Impact factor: 4.335

7.  Performance of computer simulated inhalational anesthetic uptake model in comparison with real time isoflurane concentration.

Authors:  Umeshkumar Athiraman; M Ravishankar; Sameer Jahagirdhar
Journal:  J Clin Monit Comput       Date:  2015-09-19       Impact factor: 2.502

8.  Propofol emulsion reduces proliferative responses of lymphocytes from intensive care patients.

Authors:  C O Pirttikangas; J Perttilä; M Salo
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 9.  Practical treatment recommendations for the safe use of anaesthetics.

Authors:  J W Sear
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

10.  External Validation of a Recently Developed Population Pharmacokinetic Model for Hydromorphone During Postoperative Pain Therapy.

Authors:  Harald Ihmsen; Doris Rohde; Jürgen Schüttler; Christian Jeleazcov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.